Hormonal
Exposure to environmental obesogens (e.g., tributyltin, BPA, phthalates) increases susceptibility to obesity by altering developmental programming of stem cells and metabolic regulation, independent of caloric intake.
Minimize exposure to known obesogens like BPA (plastics), phthalates, and organotins (marine contaminants, PVC pipes). Use glass or stainless steel containers, avoid heating food in plastic, and choose fresh over processed foods to reduce intake of additives and packaging leachates, especially during pregnancy and early childhood.
The obesogen hypothesis proposes that there are chemicals in our environment termed 'obesogens' that can impact individual susceptibility to obesity and thus help explain the recent large increases in obesity and obesity susceptibility.
Why this rating
Strong animal model data and emerging human epidemiological links, though direct causal proof in humans is still evolving.
Source
Environmental Obesogens and Their Impact on Susceptibility to Obesity: New Mechanisms and Chemicals
Riann Jenay Egusquiza et al. · Endocrinology · 2020
DOI 10.1210/endocr/bqaa024
More from this paper
- Prenatal exposure to tributyltin (TBT) permanently reprograms mesenchymal stem cells (MSCs) to favor adipogenesis over osteogenesis, leading to increased body fat and insulin resistance in offspring.Good
- Obesogens can induce transgenerational obesity through epigenetic modifications (DNA methylation, histone retention, non-coding RNA) that persist in unexposed generations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →